Similar articles

• Commentary: detection of low level viraemia in telaprevir-based triple therapy for hepatitis C virus - authors' reply.

  Maasoumy B, Wedemeyer H. Maasoumy B, et al. Aliment Pharmacol Ther. 2014 Mar;39(5):544-5. doi: 10.1111/apt.12642. Aliment Pharmacol Ther. 2014. PMID: 24494844 No abstract available.
• Detection of low HCV viraemia by repeated HCV RNA testing predicts treatment failure to triple therapy with telaprevir.

  Maasoumy B, Cobb B, Bremer B, Luk K, Halfon P, Aslam S, Manns MP, Cornberg M, Wedemeyer H. Maasoumy B, et al. Aliment Pharmacol Ther. 2014 Jan;39(1):85-92. doi: 10.1111/apt.12544. Epub 2013 Nov 10. Aliment Pharmacol Ther. 2014. PMID: 24206524
• Further evolution of hepatitis C treatment: individualized therapy.

  Smith JR, Herrera JL. Smith JR, et al. Am J Gastroenterol. 2000 Sep;95(9):2383. Am J Gastroenterol. 2000. PMID: 11007249 Review. No abstract available.
• Direct-acting antiviral-based triple therapy on alpha-fetoprotein level in chronic hepatitis C patients.

  Takayama K, Furusyo N, Ogawa E, Ikezaki H, Shimizu M, Murata M, Hayashi J. Takayama K, et al. World J Gastroenterol. 2015 Apr 21;21(15):4696-706. doi: 10.3748/wjg.v21.i15.4696. World J Gastroenterol. 2015. PMID: 25914481 Free PMC article. Clinical Trial.
• Treatment of chronic hepatitis C genotype 1 with triple therapy comprising telaprevir or boceprevir.

  Swiss Association for the Study of the Liver. Swiss Association for the Study of the Liver. Swiss Med Wkly. 2012 Feb 24;142:w13516. doi: 10.4414/smw.2012.13516. eCollection 2012. Swiss Med Wkly. 2012. PMID: 22367957 Review.